登录 | 注册

热门期刊: 细胞研究(英文版)中华医学杂志(英文版)国际临床研究杂志

相关学者

相关机构

阻塞性睡眠呼吸暂停与脂肪因子的相关研究进展

Research progress on the relationship between obstructive sleep apnea and adipokines

ES评分0   

DOI 10.12208/j.ijcr.20230056
刊名
International Journal of Clinical Research
年,卷(期) 2023, 7(2)
作者
作者单位

四川大学华西医院绵竹医院 四川绵竹 ;

摘要
阻塞性睡眠呼吸暂停(Obstructive Sleep Apnea,OSA),作为常见呼吸系统疾病的一种,它是高血压、冠心病、脑卒中等疾病的独立危险因素。在OSA的主要致病因素中,肥胖最常见且最容易逆转的因素。肥胖与OSA在疾病产生背景、病理生理进程和共患病方面有许多相似之处,二者相互影响和加重。脂肪组织不仅是储能器官,更是活跃的内分泌器官,脂肪因子在体内的调控可能存在互相协同或互相拮抗的作用。OSA患者的8-异构前列腺素、白脂素、内脂素、抵抗素、趋化素、巨噬细胞迁移抑制因子、内脏脂肪组织丝氨酸蛋白酶抑制剂血清水平明显升高,降钙素基因相关肽、6-酮-前列腺素F1α的血清水平降低,以上脂肪因子在OSA的诊断及严重程度评估中可能具有重要作用,部分脂肪因子可能作为OSA和相关性疾病的治疗新方向、新靶点。
Obstructive sleep apnea (OSA), as one of the common respiratory diseases, is an independent risk factor of hypertension, coronary heart disease and stroke. Among the main pathogenic factors of OSA, obesity is the most common and easily reversible factor. Obesity and OSA have many similarities in the background, pathophysiological process and comorbidity of the disease, and they interact and aggravate each other. Adipose tissue is not only an energy storage organ, but also an active endocrine organ. The regulation of adipose factors in the body may have a synergistic or antagonistic effect. In OSA patients, the serum levels of 8-isomeric prostaglandin, leukoprotein, visfatin, resistin, chemokine, macrophage migration inhibitor, and visceral adipose tissue serine protease inhibitor were significantly increased, and calcitonin gene-related peptide, 6-keto-prostaglandin F1 α The serum level of OSA is decreased, and the above fat factors may play an important role in the diagnosis and severity assessment of OSA. Some fat factors may serve as new directions and new targets for the treatment of OSA and related diseases.
关键词
阻塞性睡眠呼吸暂停;脂肪因子
Obstructive sleep apnea; Adipose factor
基金项目
页码 7-12
  • 参考文献
  • 相关文献


[1] 丁钐, 郭立新. 肥胖与阻塞性睡眠呼吸暂停综合征的研究进展
[J]. 临床内科杂志, 2020, 37(9):616-619. 


[2] 李兰兰, 任建功. 瘦素、脂联素与代谢综合征的相关性研究进展
[J]. 中国糖尿病杂志, 2019, 27(8):632-634. 


[3] 陈梅晞, 陈思, 周燕, 等. 脂肪因子与阻塞性睡眠呼吸暂停综合征
[J]. 临床肺科杂志, 2012, 17(04):696-698. 


[4] Tokuda F, Sando Y, Matsui H, et al. Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome
[J]. Intern Med, 2008, 47(21):1843-1849. 


[5] Basoglu OK, Sarac F, Sarac S, et al. Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome
[J]. Ann Thorac Med, 2011, 6(3):120-125. 


[6] 甄国粹, 李敏菁, 罗志扬, 等. 持续气道正压通气对睡眠呼吸暂停综合征患者瘦素、脂联素水平影响
[J]. 实用医学杂志, 2013, 29(14):2295-2296. 


[7] Sánchez-de-la-Torre M, Mediano O, Barceló A, et al. The influence of obesity and obstructive sleep apnea on metabolic hormones
[J]. Sleep Breath, 2012, 16(3): 649-656. 


[8] Bingol Z, Karaayvaz EB, Telci A, et al. Leptin and adiponectin levels in obstructive sleep apnea phenotypes
[J]. Biomark Med, 2019, 13(10):865-874. 


[9] Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness
[J]. Crit Care, 2011, 15(2):221. 


[10] Zhang DM, Pang XL, Huang R, et al. Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea
[J]. Biomed Res Int, 2018, 2018:3410135. 


[11] Dakroub A, Nasser SA, Kobeissy F, et al. Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases
[J]. J Cell Physiol, 2021. 


[12] 石明, 王正艳, 李威, 等. 阻塞性睡眠呼吸暂停低通气综合征患者血清内脂素水平与睡眠呼吸监测指标的关联性分析
[J]. 中国医刊, 2014, (7):60-62. 


[13] Xu X, Xu J. Effects of different obesity-related adipokines on the occurrence of obstructive sleep apnea
[J]. Endocr J, 2020, 67(5):485-500. 


[14] Xu T, Lin Y, Sun S, et al. Changes in four plasma adipokines before and after sleep in OSAS patients
[J]. Clin Respir J, 2017, 11(6):968-974. 


[15] Huang Z, Xie X.
[Chemerin induces insulin resistance in C2C12 cells through nuclear factor-κB pathway-mediated inflammatory reaction]
[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2015, 31(6):725-729. 


[16] Zhang R, Liu S, Guo B, et al. Chemerin induces insulin resistance in rat cardiomyocytes in part through the ERK1/2 signaling pathway
[J]. Pharmacology, 2014, 94(5-6):259-264. 


[17] Weng C, Shen Z, Li X, et al. Effects of chemerin/ CMKLR1 in obesity-induced hypertension and potential mechanism
[J]. Am J Transl Res, 2017, 9(6):3096-3104. 


[18] Wen J, Wang J, Guo L, et al. Chemerin stimulates aortic smooth muscle cell proliferation and migration via activation of autophagy in VSMCs of metabolic hypertension rats
[J]. Am J Transl Res, 2019, 11(3): 1327-1342. 


[19] 周璇, 周燕. 内脏脂肪因子vaspin研究进展
[J]. 世界最新医学信息文摘, 2017, 17(A2):96-99. 


[20] Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes
[J]. Biochem Biophys Res Commun, 2006, 339(1):430-436. 


[21] Mazur-Bialy AI. Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature
[J]. Nutrients, 2021, 13(2). 


[22] Zhang Z, Tan Y, Zhu L, et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway
[J]. Life Sci, 2019, 231:116554. 


[23] Ding J, Wang S, Tan W, et al. Association of serum asprosin concentrations with obstructive sleep apnea syndrome
[J]. Sleep Breath, 2021. 


[24] 朱勇, 赵迎新. 脂肪因子网膜素1在冠状动脉粥样硬化性心脏病领域的相关研究进展
[J]. 中国医药, 2018, 13(04):624-627. 


[25] 陈晓东, 卓宋明. 网膜素与呼吸系统疾病的相关研究进展
[J]. 医学综述, 2017, 23(07):1296-1299+1304. 


[26] Wang Q, Feng X, Zhou C, et al. Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome
[J]. Ann Clin Biochem, 2013, 50(Pt 3):230-235. 


[27] Zirlik S, Hildner KM, Targosz A, et al. Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome?
[J]. J Physiol Pharmacol, 2013, 64(3):353-360. 


[28] Takahashi K, Chin K, Akamizu T, et al. Acylated ghrelin level in patients with OSA before and after nasal CPAP treatment
[J]. Respirology, 2008, 13(6):810-816. 


[29] Uygur F, Tanrıverdi H, Can M, et al. Association between continuous positive airway pressure and circulating omentin levels in patients with obstructive sleep apnoea
[J]. Sleep Breath, 2016, 20(3):939-945. 


[30] Jaikanth C, Gurumurthy P, Cherian KM, et al. Emergence of omentin as a pleiotropic adipocytokine
[J]. Exp Clin Endocrinol Diabetes, 2013, 121(7):377-383. 


[31] Song R, Wang X, Mao Y, et al. Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3β
[J]. Gene, 2013, 529(1):50-56. 


[32] Liu X, Zheng X, Su X, et al. Plasma Resistin Levels in Patients with Acute Aortic Dissection: A Propensity Score-Matched Observational Case-Control Study
[J]. Med Sci Monit, 2018, 24:6431-6437. 


[33] 潘航程, 蔡伟, 张秀伟, 等. 阻塞性睡眠呼吸暂停综合征患者抵抗素水平与血管内皮功能相关性以及干预治疗的研究
[J]. 国际呼吸杂志, 2018, 38(07):522-525. 


[34] Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease
[J]. Nat Rev Immunol, 2011, 11(2):85-97. 


[35] 刘维英. 血管活性肽与阻塞性睡眠呼吸暂停综合征
[J]. 国际呼吸杂志, 2011, (07):544-546. 


[36] 李晓艳, 黄从新, 孙有刚, 等. 降钙素基因相关肽对人血管平滑肌细胞增殖的抑制作用
[J]. 中国动脉硬化杂志, 2000, (02):153. 


[37] 谭杰. 睡眠呼吸暂停综合征患者血浆内皮素、降钙素基因相关肽水平的测定及其意义
[J]. 实用医学杂志, 2007, (07):988-989. 


[38] 邓安春, 孟祥贵, 杨桦, 等. 一氧化氮和降钙素基因相关肽在阻塞性睡眠呼吸暂停低通气综合征患者咽组织及血浆中的分布及变化
[J]. 中华耳鼻咽喉科杂志, 2004, (10): 49-53. 


[39] Edwards KM, Tomfohr LM, Mills PJ, et al. Macrophage migratory inhibitory factor (MIF) may be a key factor in inflammation in obstructive sleep apnea
[J]. Sleep, 2011, 34(2):161-163. 


[40] 周丹丹, 余娇娇, 花芳, 等. 巨噬细胞迁移抑制因子, 连接炎症和肿瘤的关键蛋白
[J]. 药学学报, 2018, 53(11): 1761-1769. 


[41] 汪敏, 林勇, 孙思庆. 阻塞性睡眠呼吸暂停低通气综合征患者血清8-异构前列腺素及超敏C反应蛋白的检测
[J]. 中国医药导报, 2010, 7(27):22-24. 


[42] 符沙沙, 欧宗兴, 陈宗存, 等. 慢性阻塞性肺疾病合并阻塞性睡眠呼吸暂停低通气综合征与脂联素、8-异前列腺素F_(2α)的关系
[J]. 中国现代医学杂志, 2019, 29(13):51-55. 


[43] 吴坎金, 安泽余, 关继涛, 等. 阻塞性睡眠呼吸暂停低通气综合征患者血栓素B_26-酮-前列腺素F1α和抗心磷脂抗体检测的临床研究
[J]. 中华结核和呼吸杂志, 2004, (05):35-38. 

  • 文献评论